← Eichor
Study identifier: NCT07562178 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Pemafibrate for Symptomatic ICAS RCT

Condition: Intracranial Atherosclerotic Disease (ICAD) · Hypertriglyceridaemia · Stroke (CVA) or TIA  ·  Sponsor: Tokyo Women's Medical University

PhaseNA
Planned participants270
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn whether pemafibrate can help prevent worsening of intracranial arterial stenosis (ICAS) in patients who have symptomatic ICAS and high triglycerides (TG) levels after ischemic stroke or transient ischemic attack (TIA). The main questions this study aims to answer are: 1. Does pemafibrate lower the chance that ICAS gets worse over 12 months? 2. Does pemafibrate improve TG levels and other vascular risk markers? 3. What are the effects of pemafibrate on vascular events, functional outcomes, and safety over 12 months? Researchers will compare a pemafibrate group with a non-pemafibrate group to see whether pemafibrate helps prevent progression of ICAS. This is an open-label, randomized, parallel-group trial. That means participants are assigned by chance to 1 of 2 groups, and both the researchers and participants know which group was assigned. Participants in both groups will continue to receive standard stroke care, including antithrombotic therapy and management of vascular risk factors such as blood pressure, low-density lipoprotein cholesterol, diabetes, and smoking. Participants may be eligible if they are 18 years or older, have clinically stable ischemic stroke or TIA, have 50% to 99% stenosis in a symptomatic intracranial artery on contrast-enhanced CT angiography (CTA), and have elevated fasting (\>=150 mg/dL) or non-fasting (\>=175 mg/dL) TG levels. Some people will not be eligible, such as those with ICAS due to non-ather…

This description comes directly from the study's public registry record.

Talk to the study team

Kenichi Todo, MD, PhD  ·  +81-3-3353-8111  ·  todo.kenichi@twmu.ac.jp

Takao Hoshino, MD, PhD  ·  +81-3-3353-8111  ·  hoshino.takao@twmu.ac.jp

Always discuss trial participation with your own doctor first.

Locations (19)

Iwate Medical University HospitalHizume, Iwate, JapanRecruiting
Kagoshima Medical CenterKagoshima, Kagoshima-ken, JapanRecruiting
Kumamoto University HospitalKumamoto, Kumamoto, JapanRecruiting
Japanese Red Cross Kyoto Daini HospitalKyoto, Kyoto, JapanRecruiting
University Hospital Kyoto Prefectural University of MedicineKyoto, Kyoto, JapanRecruiting
Nagasaki University HospitalNagasaki, Nagasaki, JapanNot Yet Recruiting
Kawasaki Medical School HospitalKurashiki, Okayama-ken, JapanRecruiting
Kansai Medical University HospitalHirakata, Osaka, JapanRecruiting
Osaka National HospitalOsaka, Osaka, JapanRecruiting
Osaka General Medical CenterOsaka, Osaka, JapanRecruiting
Saitama Medical University International Medical CenterHidaka, Saitama, JapanNot Yet Recruiting
Japanese Red Cross Saitama HospitalSaitama, Saitama, JapanNot Yet Recruiting

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07562178